INmune Bio Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
RJ Tesi
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 29.5% |
| CEO tenure | 9yrs |
| CEO ownership | 7.8% |
| Management average tenure | 9yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year
Jul 12
Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?
Jan 19Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Sep 04Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
May 12Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jan 16Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jul 11INmune Bio: Possibly The Once In A Lifetime Dip
May 25INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors
Apr 05Is INmune Bio (NASDAQ:INMB) A Risky Investment?
Mar 25Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
Dec 02INmune Bio A No-Brainer Investment
Oct 13INmune Bio: High-Risk High-Reward Alzheimer's Play
Aug 18Our Bullish Take On INmune Bio's Drug Pipeline
Aug 12INmune Bio: Underfollowed AD Player With Very Bullish August Momentum
Jul 13Companies Like INmune Bio (NASDAQ:INMB) Are In A Position To Invest In Growth
Jun 25INmune enters $15M credit facility to fund purchase of Xencor option
Jun 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$38m |
| Mar 31 2024 | n/a | n/a | -US$34m |
| Dec 31 2023 | US$2m | US$501k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$1m | US$455k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$31m |
| Jun 30 2022 | n/a | n/a | -US$33m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | US$3m | US$455k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$24m |
| Jun 30 2021 | n/a | n/a | -US$19m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$300k | US$300k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | US$1m | US$248k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$7m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$3m | US$120k | -US$12m |
Compensation vs Market: RJ's total compensation ($USD1.69M) is above average for companies of similar size in the US market ($USD683.22K).
Compensation vs Earnings: RJ's compensation has increased whilst the company is unprofitable.
CEO
RJ Tesi (68 yo)
9yrs
Tenure
US$1,694,818
Compensation
Dr. Raymond Joseph Tesi, MD, also known as RJ, serves as Director at Bexion Pharmaceuticals, Inc. Dr. Tesi is the Co-Founder of INmuneBio Inc. and has been its Chief Medical Officer and Chairman and serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9yrs | US$1.69m | 7.79% $ 10.2m | |
| CFO, Treasurer & Secretary | 9yrs | US$1.59m | 6.42% $ 8.4m | |
| Chief Scientific Officer & Chief Manufacturing Officer | 8.9yrs | US$150.24k | 7.65% $ 10.0m | |
| General Counsel | 5.7yrs | no data | no data |
9.0yrs
Average Tenure
61yo
Average Age
Experienced Management: INMB's management team is seasoned and experienced (9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9yrs | US$1.69m | 7.79% $ 10.2m | |
| Independent Director | 4.8yrs | US$301.66k | no data | |
| Independent Director | 6.5yrs | US$301.66k | 0.36% $ 474.0k | |
| Independent Director | 8yrs | US$301.66k | 0.090% $ 117.8k | |
| Independent Director | 7.8yrs | US$301.26k | 0.42% $ 544.1k |
7.8yrs
Average Tenure
66yo
Average Age
Experienced Board: INMB's board of directors are considered experienced (7.8 years average tenure).